Alcohol withdrawal syndrome management: Is there anything new?;La prise en charge du syndrome de sevrage de l'alcool: quelles nouveautés ?

Revue de Medecine Interne

Volumn 40, Issue 6, 2019, Pages 373-379

  Airagnes, G ^a,b,c   Ducoutumany, G ^a,b   Laffy Beaufils, B ^a,b   Le Faou, A L ^a,b,d   Limosin, F ^a,b,e  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UMS 011   (France)

^d Paris Diderot University   (France)

^e INSERM   (France)

Author keywords

Addiction; Alcohol use disorder; Alcohol withdrawal syndrome; Benzodiazepine; Delirium; Detoxification

Indexed keywords

BENZODIAZEPINE; FOLIC ACID; GLUTAMIC ACID; THIAMINE; ALCOHOL;

AFTERCARE; ALCOHOL ABSTINENCE; ALCOHOL WITHDRAWAL SYNDROME; DETOXIFICATION; DISEASE COURSE; DRUG EFFICACY; HUMAN; LOADING DRUG DOSE; NEUROTOXICITY; RISK; SHORT SURVEY; ALCOHOLISM; COMPLICATION; WITHDRAWAL SYNDROME;

ALCOHOL-INDUCED DISORDERS; ETHANOL; HUMANS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 85062394944     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2019.02.001     Document Type: Short Survey

References (69)

1. World Health Organization, Global status report on alcohol and health 2014. 2014, World Health Organization, Geneva [xiv, 376 p.].
2. Paille, F., Reynaud, M., L'alcool, une des toutes premières causes d'hospitalisation en France. Bull Epidemiol Hebd 24–25 (2015), 440–449.
3. Mirijello, A., D'Angelo, C., Ferrulli, A., Vassallo, G., Antonelli, M., Caputo, F., et al. Identification and management of alcohol withdrawal syndrome. Drugs 75 (2015), 353–365.
4. Drummond, C., Gual, A., Goos, C., Godfrey, C., Deluca, P., Von Der Goltz, C., et al. Identifying the gap between need and intervention for alcohol use disorders in Europe. Addiction 106:Suppl. 1 (2011), 31–36.
5. Reoux, J.P., Malte, C.A., Kivlahan, D.R., Saxon, A.J., The Alcohol Use Disorders Identification Test (AUDIT)predicts alcohol withdrawal symptoms during inpatient detoxification. J Addict Dis 21 (2002), 81–91.
6. Kattimani, S., Bharadwaj, B., Clinical management of alcohol withdrawal: a systematic review. Ind Psychiatry J 22 (2013), 100–108.
7. Mainerova, B., Prasko, J., Latalova, K., Axmann, K., Cerna, M., Horacek, R., et al. Alcohol withdrawal delirium – diagnosis, course and treatment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159 (2015), 44–52.
8. Mayo-Smith, M.F., Beecher, L.H., Fischer, T.L., Gorelick, D.A., Guillaume, J.L., Hill, A., et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med 164 (2004), 1405–1412.
9. Maldonado, J.R., Sher, Y., Das, S., Hills-Evans, K., Frenklach, A., Lolak, S., et al. Prospective Validation Study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS)in medically ill inpatients: a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol Alcohol 50 (2015), 509–518.
10. Muncie, H.L. Jr., Yasinian, Y., Oge, L., Outpatient management of alcohol withdrawal syndrome. Am Fam Physician 88 (2013), 589–595.
11. Kopelman, M.D., Thomson, A.D., Guerrini, I., Marshall, E.J., The Korsakoff syndrome: clinical aspects, psychology and treatment. Alcohol Alcohol 44 (2009), 148–154.
12. Agence nationale d'accréditation et d’évaluation en santé, Société française d'alcoologie, Conférence de consensus. Objectifs, indications et modalités du sevrage du patient alcoolodépendant. 1999 https://www.has-sante.fr/portail/jcms/c_267098/fr/sevrage-alcool-recommandations-version-longue-pdf.
13. Dhanda A, Morgan M, Simpson L, Jugdoyal A, Bhala N, Gittins R. Alcohol use disorders: diagnosis and clinical management of alcohol-related physical complications. NICE clinical guideline. 2010 https://www.nice.org.uk/guidance/cg100.
14. Société française d'alcoologie, Évaluation des pratiques professionnelles en alcoologie. Référentiel de bonnes pratiques cliniques. Sevrage simple en alcool. 2006 https://www.sfalcoologie.asso.fr/download/Svg_simple.pdf.
15. O'Daly, O.G., Trick, L., Scaife, J., Marshall, J., Ball, D., Phillips, M.L., et al. Withdrawal-associated increases and decreases in functional neural connectivity associated with altered emotional regulation in alcoholism. Neuropsychopharmacology, 37, 2012, 2267.
16. Loeber, S., Duka, T., Welzel, H., Nakovics, H., Heinz, A., Flor, H., et al. Impairment of cognitive abilities and decision-making after chronic use of alcohol: the impact of multiple detoxifications. Alcohol Alcohol 44 (2009), 372–381.
17. Moos, R.H., Moos, B.S., Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction 101 (2006), 212–222.
18. Sarai, M., Tejani, A.M., Chan, A.H., Kuo, I.F., Li, J., Magnesium for alcohol withdrawal. Cochrane Database Syst Rev, 6, 2013, CD008358.
19. Yates, W.R., Booth, B.M., Reed, D.A., Brown, K., Masterson, B.J., Descriptive and predictive validity of a high-risk alcoholism relapse model. J Stud Alcohol 54 (1993), 645–651.
20. Kouimtsidis, C., Charge, K.-J., Moch, J.P., Stahl, D., Abstinence preparation group intervention for dependent alcohol users. How does it work? Results of a process study. J Subst Use 22 (2017), 149–155.
21. Chutuape, M.A., Katz, E.C., Stitzer, M.L., Methods for enhancing transition of substance dependent patients from inpatient to outpatient treatment. Drug Alcohol Depend 61 (2001), 137–143.
22. Norstrom, T., Skog, O.J., Alcohol and mortality: methodological and analytical issues in aggregate analyses. Addiction 96:Suppl. 1 (2001), S5–S17.
23. Friend, K.B., Pagano, M.E., Smoking cessation and alcohol consumption in individuals in treatment for alcohol use disorders. J Addict Dis 24 (2005), 61–75.
24. Gulliver, S.B., Kamholz, B.W., Helstrom, A.W., Smoking cessation and alcohol abstinence: what do the data tell us?. Alcohol Res Health, 29, 2006, 208.
25. Shelton, K.H., Taylor, P.J., Bonner, A., van den Bree, M., Risk factors for homelessness: evidence from a population-based study. Psychiatr Serv 60 (2009), 465–472.
26. Hwang, S.W., Burns, T., Health interventions for people who are homeless. Lancet 384 (2014), 1541–1547.
27. Lemogne, C., Psychiatrie de liaison. 2018, Médecine Sciences Publications. Paris, France: Lavoisier.
28. Morley, K.C., Lintzeris-Haber, P.S., Guidelines for the treatment of alcohol problems. 2009, Australian Government Department for Health and Aging. Sydney, Australia [http://www.alcohol.gov.au/internet/alcohol/publishing.nsf/Content/73255B4E8D13C81DCA257DB70003CFE1/$File/AustAlctreatguidelines%202009.pdf].
29. Engelander, M., Frei, M., Alcohol, T.P., Health, D.C.-E., Berends, L., Kenny, P., et al. Alcohol and other drug withdrawal: practice guidelines. 2018, Turning Point Alcohol and Drug Centre Incorporated. Victoria, Australia [https://www.turningpoint.org.au/sites/default/files/inline-files/Alcohol-and-Drug-Withdrawal-Guidelines-2018.pdf].
30. Ward, D., Murch, N., Agarwal, G., Bell, D., A multi-centre survey of inpatient pharmacological management strategies for alcohol withdrawal. QJM 102 (2009), 773–780.
31. Jesse, S., Brathen, G., Ferrara, M., Keindl, M., Ben-Menachem, E., Tanasescu, R., et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand 135 (2017), 4–16.
32. Rolland, B., Paille, F., Gillet, C., Rigaud, A., Moirand, R., Dano, C., et al. Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther 22 (2016), 25–37.
33. Limosin, F., Loze, J.Y., Boni, C., Fedeli, L.P., Hamon, M., Rouillon, F., et al. The A9 allele of the dopamine transporter gene increases the risk of visual hallucinations during alcohol withdrawal in alcohol-dependent women. Neurosci Lett 362 (2004), 91–94.
34. Goodson, C.M., Clark, B.J., Douglas, I.S., Predictors of severe alcohol withdrawal syndrome: a systematic review and meta-analysis. Alcohol Clin Exp Res 38 (2014), 2664–2677.
35. Khan, A., Levy, P., DeHorn, S., Miller, W., Compton, S., Predictors of mortality in patients with delirium tremens. Acad Emerg Med 15 (2008), 788–790.
36. Schuckit, M.A., Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med 371 (2014), 2109–2113.
37. AFSSAPS, État des lieux de la consommation de benzodiazépines en France. Rapport d'expertise. 2012 https://ansm.sante.fr/content/download/38059/500324/version/2/file/Afssaps_Rapport-Benzodiazepines_Janvier_2012.pdf.
38. Airagnes, G., Pelissolo, A., Lavallee, M., Flament, M., Limosin, F., Benzodiazepine misuse in the elderly: risk factors, consequences, and management. Curr Psychiatry Rep, 18, 2016, 89.
39. Linnoila, M.I., Benzodiazepines and alcohol. J Psychiatr Res 24 (1990), 121–127.
40. Tanaka, E., Toxicological interactions between alcohol and benzodiazepines. J Toxicol Clin Toxicol 40 (2002), 69–75.
41. Daeppen, J., Gache, P., Landry, U., et al. Symptom-triggered vs. fixed schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 162 (2002), 1117–1121.
42. Sachdeva, A., Choudhary, M., Chandra, M., Alcohol withdrawal syndrome: benzodiazepines and beyond. J Clin Diagn Res 9 (2015), VE01–VE07.
43. Flannery, A.H., Adkins, D.A., Cook, A.M., Unpeeling the evidence for the banana bag: evidence-based recommendations for the management of alcohol-associated vitamin and electrolyte deficiencies in the ICU. Crit Care Med 44 (2016), 1545–1552.
44. Latt, N., Dore, G., Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Intern Med J 44 (2014), 911–915.
45. Noui, S., Dervaux, A., Syndrome de sevrage à l'alcool: quoi de neuf ?. Courrier Addictions, 19, 2017:21–2.
46. Schmidt, K.J., Doshi, M.R., Holzhausen, J.M., Natavio, A., Cadiz, M., Winegardner, J.E., Treatment of severe alcohol withdrawal. Ann Pharmacother 50:5 (2016), 389–401.
47. Jesse, S., Bråthen, G., Ferrara, M., Keindl, M., Ben-Menachem, E., Tanasescu, R., et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand 135 (2017), 4–16.
48. McLean, R.M., Magnesium and its therapeutic uses: a review. Am J Med 96:1 (1994), 63–76.
49. Nechifor, M., Magnesium in drug dependences. Magnes Res 21 (2008), 5–15.
50. Jacka, F.N., Overland, S., Stewart, R., Tell, G.S., Bjelland, I., Mykletun, A., Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study. Aust N Z J Psychiatry 43 (2009), 45–52.
51. Seelig, M.S., Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review). J Am Coll Nutr 13 (1994), 429–446.
52. Sartori, S.B., Whittle, N., Hetzenauer, A., Singewald, N., Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment. Neuropharmacology 62 (2012), 304–312.
53. Murck, H., Magnesium and affective disorders. Nutr Neurosci 5:6 (2002), 375–389.
54. Poikolainen, K., Alho, H., Magnesium treatment in alcoholics: a randomized clinical trial. Subst Abuse Treat Prev Policy, 3, 2008, 1.
55. Prior, P.L., Vaz, M.J., Ramos, A.C., Galduroz, J.C., Influence of microelement concentration on the intensity of alcohol withdrawal syndrome. Alcohol Alcohol 50 (2015), 152–156.
56. Liu, J., Wang, L.N., Baclofen for alcohol withdrawal. Cochrane Database Syst Rev, 2013, CD008502.
57. Leone, M.A., Vigna-Taglianti, F., Avanzi, G., Brambilla, R., Faggiano, F., Gamma-hydroxybutyrate (GHB)for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev, 2010, CD006266.
58. Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev, 2010, CD005064.
59. Brotherton, A.L., Hamilton, E.P., Kloss, H.G., Hammond, D.A., Propofol for treatment of refractory alcohol withdrawal syndrome: a review of the literature. Pharmacotherapy 36 (2016), 433–442.
60. Bielka, K., Kuchyn, I., Glumcher, F., Addition of dexmedetomidine to benzodiazepines for patients with alcohol withdrawal syndrome in the intensive care unit: a randomized controlled study. Ann Intensive Care, 5, 2015, 33.
61. Martin, K., Katz, A., The role of barbiturates for alcohol withdrawal syndrome. Psychosomatics 57 (2016), 341–347.
62. Zindel, L.R., Kranzler, H.R., Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J Stud Alcohol Suppl 17 (2014), 79–88.
63. Connor, J.P., Haber, P.S., Hall, W.D., Alcohol use disorders. Lancet 387 (2016), 988–998.
64. Mann, K., Kiefer, F., Spanagel, R., Littleton, J., Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 32 (2008), 1105–1110.
65. Rehm, J., Zatonksi, W., Taylor, B., Anderson, P., Epidemiology and alcohol policy in Europe. Addiction 106:Suppl. 1 (2011), 11–19.
66. van Amsterdam, J., van den Brink, W., Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence. J Psychopharmacol 27 (2013), 987–997.
67. ANSM, Communiqué. L'ANSM octroie une autorisation de mise sur le marché pour une utilisation du baclofène dans l'alcoolo-dépendance. 2018 https://ansm.sante.fr/content/download/151291/1989105/version/1/file/Baclocur+40mg+RCP_1.pdf.
68. Menecier, P., Prieur, V., Arèzes, C., Menecier, L., Rotheval, L., L'alcool et le sujet âgé en institution. Gerontol Soc 26 (2003), 133–149.
69. Alencar, L.E., Martinez, A., Fernandez, C., Garaulet, M., Perez-Llamas, F., Zamora, S., Dietary intake in adolescents from southeast Spain and its relationship with physical activity. Nutr Hosp 15 (2000), 51–57.